INTRODUCTION
Activated Hageman factor (HF,1 Factor XII) participates in the surface-mediated reactions of clotting, esterase-and kinin-generation, fibrinolysis, and enhancement of vascular permeability. These properties of HF are mediated or intensified by Fletcher factor, a plasma prekallikrein deficient in Fletcher trait (1, 2) . In early experiments, crude activated HF appeared to activate plasma thromboplastin antecedent (PTA, Factor XI) enzymatically (3) . When more purified systems became available, activation of PTA by activated HF was no longer demonstrable (4) . Although activated Fletcher factor (a plasma kallikrein) is needed for optimal activation of PTA (2) , incubation of a mixture of HF, PTA, prekallikrein, and kaolin still did not result in activation of PTA (4) . These observations suggest that the activation of PTA requires the presence of one or more additional agents.
This report describes studies in an asymptomatic 71-yr-old man in whom a defect in the intrinsic pathway of thrombin formation was detected by chance (5) . His plasma was apparently deficient in a hitherto unrecog-nized factor needed for expression of the functions of activated HF (6) . With his permission we have named his disorder Fitzgerald trait, and the agent functionally deficient in his plasma, Fitzgerald factor. A similar patient, described by Colman, Bagdasarian, Talamo, and Kaplan (7) while our studies were in progress, appears to have an identical defect.
METHODS
Unless otherwise noted, human citrated plasma, animal plasmas, purified clotting factors, and reagents were prepared or obtained as described earlier (8) (9) (10) (11) . Fletcher trait plasma was kindly supplied by Dr. C. Abildgaard, University of California, Davis.
The effect of Celite adsorption of normal plasma upon various clotting factor activities was studied using Celite 512 (diatomaceous earth, a gift of Johns-Manville Products Corp., Celite division, New York) as described by Nossel (12) .
A crude fraction that corrected the patient's clotting defect was separated from normal or HF-deficient plasma, adsorbed for 10 min at room temperature with 1/10 vol of alumina C'y gel (Calbiochem, San Diego, Calif.). The adsorbed plasma was mixed with 1/100 vol of 0.01 M sodium EDTA and 5 mg of hexadimethrine bromide (HBr) (Aldrich Chem. Co. Inc., Milwaukee, Wis.) per ml and was dialyzed against 0.1 M sodium chloride in 0.025 M Tris-chloride buffer (pH 8.0) containing 0.0001 M EDTA and 0.05 mg HBr per ml. This material was chromatographed on a column of QAE-Sephadex A-50 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.), as described earlier (8) , ex- cept that the starting buffer contained 0.1 M sodium chloride and elution was via a linear gradient to 0.5 M NaCl in the same buffer. The molecular weight of fractions with correcting activity was examined by filtering the concentrated, pooled active fractions from a QAE-Sephadex A-50 column through a column of Sephadex G-150 (Pharmacia Fine Chemicals Inc.) equilibrated with a barbital-saline buffer (8) . In one experiment with HF-deficient plasma, fractions with corrective activity were concentrated, dialyzed against 0.05 M sodium acetate buffer (pH 52) containing 0.15 M sodium chloride and 0.0001 M EDTA, and chromatographed upon SP-Sephadex C-50 (Pharmacia Fine Chemicals Inc.), as described earlier (8) .
Batch preparation of the corrective fraction of normal plasma was performed as follows. 2-ml plasma was adsorbed with alumina CGy gel, mixed with EDTA and HBr, and dialyzed against 0.1 M sodium chloride in a Tris-chloride-EDTA-HBr buffer as described above. The dialyzed plasma was mixed for 10 min at room temperature with an equal volume of QAE-Sephadex A-50, equilibrated with the same buffer in a 12 X 75-mm polystyrene tube. After centrifugation, the supernatant plasma was discarded and the precipitate was washed repeatedly with 10-ml portions of buffer until the washings no longer formed a visible precipitate upon addition of an equal volume of 10% trichloroacetic acid. The washed QAE-Sephadex was then eluted twice for 10 min with 2-ml portions of 0.5 M sodium chloride in a Tris-chloride-EDTA-HBr buffer; each eluate was diluted and assayed for Fitzgerald factor activity. The patient's plasma was fractionated in the same way.
Procoagulant assays for various clotting factors (8) , immunologic assays for HF (13) and AHF (Factor VIII) (14) , kaolin-activated plasma esterolytic activity for ptoluenesulfonyl-L-arginine methyl ester (TAME) (15) , kaolin-induced fibrinolytic activity (10), antiplasmin (10), C1 inactivator titer (16) , and vascular permeability (17) were assayed as described earlier. Immunodiffusion was performed in a 0.9% agarose gel in a 0.05 M barbital buffer (pH 8.6) for 2 days at room temperature. A functional assay for the patient's deficient factor, based upon the kaolin-activated partial thromboplastin time (PTT) was devised. A volume of 0.1 ml each of the test sample, suitably diluted in barbital-saline buffer, a mixture of kaolin (10 mg/ml) and phospholipid (0.1% in saline, Centrolex "O," the gift of Central Soya Co., Inc., Chicago, Ill.), and the patient's plasma were incubated together for 1 min at 37°C in a 10 X 75-mm glass tube; studies performed subsequent to those in the present report suggest that a preliminary period of incubation of 8 min is superior to a 1-min period. The mixture was recalcified with 0.1 ml 0.025 M calcium chloride, and the clotting time was measured. The clotting time was converted to percentage activity by comparison with a calibration curve prepared by assaying serial dilutions of a standard pool of normal plasma (14); a linear relationship existed between the logarithm of the clotting time and the logarithm of 1/20 to 1/200 dilutions of the pooled plasma.
The effect upon the PTT of the patient's plasma by the addition of trypsin-activated PTA, kaolin-activated HF, and kallikrein (10) , and the effect upon the Thrombotest time of incubating plasma with kaolin at 0°C were studied as described (18) .
Generation of kinin-like activity was tested on the estrous rat uterus, adding atropine sulfate (1 ,ug per ml) to the deJalon's solution (19) . In some experiments, kinin generation was estimated from the duration of delay between addition of the sample and the onset of contraction, an inverse function of the concentration of kinins (20) . The effect of addition of ellagic acid or HF-fragments upon kinin generation was tested as described in Table II . The effect of plasma kallikrein upon kinin generation was tested in a mixture of 0.025 ml kallikrein (68 jsmol MeOH released/ml per h, specific activity 755 ,umol MeOH/mg protein per h), 0.05 ml test plasma, 0.05 ml 0.01 M o-phenanthroline (Fisher Scientific Co., Inc., Pittsburgh, Pa.), and 0.35 ml barbital-saline buffer (pH 7.4) at 37°C in 12 X 75-mm polystyrene tubes, testing samples for kinin-like activity. Kininogen in boiled plasma was measured as described by Diniz and Carvalho (21) . Kinase was estimated by a modification of an earlier technique (22) , incubating 5 igg of bradykinin (the gift of Sandoz Pharmaceuticals, Hanover, N. J.) in 0.05 ml barbital-saline buffer with 0.1 ml of the test plasma and 1.8 ml of the same buffer in 12 X 75-mm polystyrene tubes at 370C. At intervals, 0.1-ml portions were added to a similar polystyrene tube containing 0.2 ml of 0.001 M o-phenanthroline and 1.6 ml of buffer and were tested immediately for kinin-like activity.
RESULTS
Studies on the clotting defect in Fitzgerald trait. The kaolin-activated PTT of the patient's plasma was abnormally long (> 500 s; control, 54 s), whereas the one-stage prothrombin time was normal, localizing the functional defect to the initial steps of the intrinsic pathway. Functional concentrations of HF, PTA, Christmas factor (Factor IX), and antihemophilic factor (AHF) were normal, while that of Fletcher factor was 10-15% that of pooled normal plasma (5) . Immunologic assays (Table I) , as if the patient's defect were at a step after activation of HF and Fletcher factor but before participation of activated PTA.
The agent in normal plasma correcting the patient's clotting defect was stable at -70°C for at least 2 yr, and it lost only 20% activity after heating of plasma at 56°C for 30 min. It was not significantly adsorbed from oxalated plasma by tricalcium phosphate (10 mg/ml) or from citrated plasma by alumina C'v gel. It was not significantly removed by small amounts of Celite (1 2 mg/ml plasma), whereas most of PTA and Fletcher factor activity was adsorbed under these conditions (Fig. 1) . When normal plasma was adsorbed with 5 mg Celite 512 per ml plasma, and the supernatant plasma was incubated at 37°C for 18 h, it contained approximately 50% of the factor correcting the patient's defect and 70% of HF activity, but almost no PTA and Fletcher factor activity. It was completely removed from plasma by Celite at a concentration of 40 mg/ml and could then be partially eluted by 10% sodium chloride in 0.05 M Tris-chloride buffer (pH 8.0). It was present in normal serum and in the fraction of plasma soluble at 20% and insoluble at 60% saturation with neutral ammonium sulfate. Unlike PTA, Fletcher factor and the precursor of HF-cofactor (an agent needed for surface-mediated activation of plasminogen [23] ), the corrective agent was adsorbed from normal or HFdeficient plasma onto columns of QAE-Sephadex A-50, an anionic resin, from which it could be eluted at an ionic strength slightly higher than that releasing HF; 1084 H. Saito gerald trait and Fletcher trait plasma. 0.1 ml test plasma was incubated with 0.1 ml kaolin suspension (10 mg/ml 0.1 M sodium phosphate buffer, pH 7.5 in 0.15 M NaCl) in 12 X 75-mm polystyrene tubes at 25°C. At intervals, 2 ml of ice-cold 0.05 M TAME was added to the tubes and esterase activity was measured as described in the Methods section. After centrifugation, the supernatant solution was discarded and the euglobulin precipitate, containing kaolin, was resuspended in 0.5 ml barbital-saline buffer. 0.2-ml portions of the euglobulin-kaolin suspension were mixed with 0.1 ml bovine fibrinogen (3 mg/ml) and 0.1 ml bovine thrombin (Parke Davis & Co., Detroit, Mich.) in 10 X 75-mm polystyrene tubes. The clot lysis time was measured at 370C.
fective in HF-deficient and Fletcher factor-deficient plasmas (11, 15) , has been ascribed to generation of a plasma kallikrein (15) . Evolution of esterolytic activity, tested upon TAME, was deficient in the patient's plasma and was only partially corrected by addition of Fletcher trait plasma, presumably because the patient's plasma contained diminished amounts of prekallikrein and Fletcher trait plasma contained none (Fig. 2) . Studies on generation of fibrinolytic activity in Fitzgerald trait. Fibrinolytic activity generates in normal diluted and acidified plasma incubated with kaolin (26) an effect mediated by an agent called HF-cofactor (23) or plasminogen activator (27) . Generation of fibrinolytic activity in the patient's plasma was deficient, an abnormality also observed in HF-deficient and Fletcher factor-deficient plasmas (Table III) . Functional and immunodiffusion assays showed that defective generation of fibrinolytic activity in the patient's plasma was not due to deficiency of plasminogen or to increased amounts of plasmin inhibitors or fibrinogen. Defective generation of fibrinolytic activity was corrected by addition of equal volumes of HF-deficient or Fletcher factor-deficient plasma, which reduced the lysis time of fibrin clots from >120 min for each plasma alone to 8 min. Unlike Fletcher trait plasma (10), the clot lysis time of the patient's plasma was not significantly reduced by prolonged surface contact before acidification and dilution.
Ogston, Ogston, Ratnoff, and Forbes (23) demonstrated that HF-induced fibrinolysis required the presence not only of HF-cofactor but also of an ill-defined additional agent. This substance, previously found in 0.05 ml plasma was diluted with 4.95 ml 0.0001 M ellagic acid or with barbital-saline buffer in 13 X 100-mm silicone-coated glass tubes. Each tube was incubated at 370C and, at the time indicated, 0.1-ml samples were injected intracutaneously into each of four guinea pigs. The permeability-enhancing activity was measured as described in the Methods sections as the mean diameter of blued spots.
Fletcher trait plasma (10) , was also present in the patient's plasma. Studies on the generation of PF/Dil in Fitzgerald trait. Normal plasma, diluted and incubated with ellagic acid, enhances vascular permeability in guinea pig skin (28) . This property, designated PF/Dil, does not appear in similarly treated HF-deficient (28) or Fletcher factor-deficient (2, 10) plasmas, nor did it in the patient's plasma, whereas PF/Dil developed in an equal mixture of the patient's plasma and either of the other two (Table IV) . The addition of ellagic acidactivated HF or HF fragments generated PF/Dil in Hageman trait plasma, but not in the patient's plasma (Table V) .
Family studies in Fitzgerald trait. We do not know the range of concentration in normal plasma of the agent apparently deficient in the patient's plasma, but that of the patient's sole surviving sister was 40% that of a pool of normal plasma, and that of his only son was 70%. The titer was 120% of the pooled plasma in an individual with Fletcher trait, and ranged from 52 to 105% in four subjects with Hageman trait and from 80 to 130% in four subjects with PTA deficiency. In the experiments reported, the prolonged activated PTT in the plasma of an asymptomatic man, Allen Fitzgerald, was related to the deficiency of an agent not identified with known clotting factors. The defect, localized to a step after activation of HF and Fletcher factor and before participation of activated PTA, was corrected by human plasma deficient in HF, PTA, or Fletcher factor, or by cetacean plasma, deficient in HF 
